BioMarin Pharmaceutical (BMRN), like the overall biotech industry ($DJUSBT), has struggled for the past 18 months to clear overhead price resistance. But over the past couple trading sessions, we have seen one biotech company after another clear resistance on strong volume and accelerate. It appears that BMRN is awaiting its turn. While its gains this week have been strong, the best may await on a breakout. Here’s the longer-term weekly chart: